November 2021 Publications
- Interleukin-23 instructs protective multifunctional CD4 T cell responses after immunization with the Mycobacterium tuberculosis subunit vaccine H1 DDA/TDB independently of interleukin-17A. Ritter K, Behrends J, Erdmann H, Rousseau J, Hölscher A, Volz J, Prinz I, Lindenstrøm T, Hölscher C. J Mol Med (Berl). 2021 Nov. doi: 10.1007/s00109-021-02100-3. Epub 2021 Aug 5.
- Comparative transcriptomic analysis of THP-1-derived macrophages infected with Mycobacterium tuberculosis H37Rv, H37Ra and BCG. Pu W, Zhao C, Wazir J, Su Z, Niu M, Song S, Wei L, Li L, Zhang X, Shi X, Wang H. J Cell Mol Med. 2021 Nov. doi: 10.1111/jcmm.16980. Epub 2021 Oct 10.
- Timing of Mycobacterium tuberculosis exposure explains variation in BCG effectiveness: a systematic review and meta-analysis. Trauer JM, Kawai A, Coussens AK, Datta M, Williams BM, McBryde ES, Ragonnet R. Thorax. 2021 Nov. doi: 10.1136/thoraxjnl-2020-216794. Epub 2021 Apr 23.
- The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi. Glynn JR, Dube A, Fielding K, Crampin AC; Karonga Prevention Trial Group, Kanjala C, Fine PEM. Lancet Infect Dis. 2021 Nov. doi: 10.1016/S1473-3099(20)30994-4. Epub 2021 Jul 5.
- An integrated computational framework to design a multi-epitopes vaccine against Mycobacterium tuberculosis. Albutti A. Sci Rep. 2021 Nov 9. doi: 10.1038/s41598-021-01283-6.
- BCG vaccination induces enhanced frequencies of memory T cells and altered plasma levels of common gammac cytokines in elderly individuals. Kumar NP, Padmapriyadarsini C, Rajamanickam A, Bhavani PK, Nancy A, Jayadeepa B, Selvaraj N, Asokan D, Renji RM, Venkataramani V, Tripathy S, Babu S. PLoS One. 2021 Nov 10. doi: 10.1371/journal.pone.0258743. eCollection 2021.
- Time to face the proofs: the BCG Moreau vaccine promotes superior inflammatory cytokine profile in vitro when compared with Russia, Pasteur, and Danish strains. da Silva ASM, Albuquerque LHP, de Ponte CGG, de Almeida MR, de Faria SER, Ribeiro MDS, Pereira ENGDS, Antas PRZ. Hum Vaccin Immunother. 2021 Nov 12. doi: 10.1080/21645515.2021.1989913. Online ahead of print.
- Characterization of O-mannosylated proteins profiling in bacillus Calmette-Guérin via gel-based and gel-free approaches. Zheng J, Liu L, Wei C, Liu B, Jin Q. IUBMB Life. 2021 Nov 13. doi: 10.1002/iub.2578. Online ahead of print.
- BCG-mediated protection against M. tuberculosis is sustained post-malaria infection independent of parasite virulence. Tangie E, Walters A, Hsu NJ, Fisher M, Magez S, Jacobs M, Keeton R. Immunology. 2021 Nov 14. doi: 10.1111/imm.13431. Online ahead of print.
- Construction and immunogenicity of a T cell epitope-based subunit vaccine candidate against Mycobacterium tuberculosis. Fan X, Li X, Wan K, Zhao X, Deng Y, Chen Z, Luan X, Lu S, Liu H. Vaccine. 2021 Nov 16. doi: 10.1016/j.vaccine.2021.10.034. Epub 2021 Oct 24.
- Single-cell transcriptomic profiles reveal changes associated with BCG-induced trained immunity and protective effects in circulating monocytes. Kong L, Moorlag SJCFM, Lefkovith A, Li B, Matzaraki V, van Emst L, Kang HA, Latorre I, Jaeger M, Joosten LAB, Netea MG, Xavier RJ. Cell Rep. 2021 Nov 16. doi: 10.1016/j.celrep.2021.110028.
- Boosting BCG with recombinant influenza A virus tuberculosis vaccines increases pulmonary T cell responses but not protection against Mycobacterium tuberculosis infection. Muflihah H, Flórido M, Lin LCW, Xia Y, Triccas JA, Stambas J, Britton WJ. PLoS One. 2021 Nov 18. doi: 10.1371/journal.pone.0259829. eCollection 2021.
- A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. Jenum S, Tonby K, Rueegg CS, Rühwald M, Kristiansen MP, Bang P, Olsen IC, Sellæg K, Røstad K, Mustafa T, Taskén K, Kvale D, Mortensen R, Dyrhol-Riise AM. Nat Commun. 2021 Nov 22. doi: 10.1038/s41467-021-27029-6.
- Robust IgM responses following intravenous vaccination with Bacille Calmette-Guerin associate with prevention of Mycobacterium tuberculosis infection in macaques. Irvine EB, O’Neil A, Darrah PA, Shin S, Choudhary A, Li W, Honnen W, Mehra S, Kaushal D, Gideon HP, Flynn JL, Roederer M, Seder RA, Pinter A, Fortune S, Alter G. Nat Immunol. 2021. 2021 Nov 22. doi: 10.1038/s41590-021-01066-1. Online ahead of print
- Designing of a Chimeric Vaccine Using EIS (Rv2416c) Protein Against Mycobacterium tuberculosis H37Rv: an Immunoinformatics Approach. Logesh R, Lavanya V, Jamal S, Ahmed N. Appl Biochem Biotechnol. 2021 Nov 24. doi: 10.1007/s12010-021-03760-0. Online ahead of print.
- A new poly(I:C)-decorated PLGA-PEG nanoparticle promotes Mycobacterium tuberculosis fusion protein to induce comprehensive immune responses in mice intranasally. Du X, Tan D, Gong Y, Zhang Y, Han J, Lv W, Xie T, He P, Hou Z, Xu K, Tan J, Zhu B. Microb Pathog. 2021 Nov 30. doi: 10.1016/j.micpath.2021.105335. Online ahead of print.